JP7044373B2 - ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途 - Google Patents

ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途 Download PDF

Info

Publication number
JP7044373B2
JP7044373B2 JP2018502145A JP2018502145A JP7044373B2 JP 7044373 B2 JP7044373 B2 JP 7044373B2 JP 2018502145 A JP2018502145 A JP 2018502145A JP 2018502145 A JP2018502145 A JP 2018502145A JP 7044373 B2 JP7044373 B2 JP 7044373B2
Authority
JP
Japan
Prior art keywords
cells
rna
activity
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018502145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520686A (ja
Inventor
ジン，シェンカン
コランテス，ジュアン－カルロス
Original Assignee
ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7044373(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー filed Critical ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー
Publication of JP2018520686A publication Critical patent/JP2018520686A/ja
Priority to JP2022037065A priority Critical patent/JP7364268B2/ja
Application granted granted Critical
Publication of JP7044373B2 publication Critical patent/JP7044373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018502145A 2015-07-15 2016-07-15 ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途 Active JP7044373B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022037065A JP7364268B2 (ja) 2015-07-15 2022-03-10 ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192876P 2015-07-15 2015-07-15
US62/192,876 2015-07-15
PCT/US2016/042413 WO2017011721A1 (fr) 2015-07-15 2016-07-15 Plate-forme d'édition génique ciblée sans nucléase et utilisations de celle-ci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022037065A Division JP7364268B2 (ja) 2015-07-15 2022-03-10 ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途

Publications (2)

Publication Number Publication Date
JP2018520686A JP2018520686A (ja) 2018-08-02
JP7044373B2 true JP7044373B2 (ja) 2022-03-30

Family

ID=57758208

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018502145A Active JP7044373B2 (ja) 2015-07-15 2016-07-15 ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
JP2022037065A Active JP7364268B2 (ja) 2015-07-15 2022-03-10 ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022037065A Active JP7364268B2 (ja) 2015-07-15 2022-03-10 ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途

Country Status (9)

Country Link
US (2) US11479793B2 (fr)
EP (2) EP3322804B1 (fr)
JP (2) JP7044373B2 (fr)
CN (1) CN108291218B (fr)
CA (2) CA3168241A1 (fr)
DK (1) DK3322804T3 (fr)
ES (1) ES2892625T3 (fr)
HK (1) HK1258288A1 (fr)
WO (1) WO2017011721A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (fr) 2011-07-22 2020-04-22 President and Fellows of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
JP7044373B2 (ja) 2015-07-15 2022-03-30 ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
IL294014B1 (en) 2015-10-23 2024-03-01 Harvard College Nucleobase editors and their uses
CN114380922A (zh) * 2016-06-15 2022-04-22 中国科学院上海营养与健康研究所 在细胞内产生点突变的融合蛋白、其制备及用途
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (fr) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Proteines de fusion cas9-recombinase programmables et utilisations associees
WO2018039438A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
WO2018119359A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Édition du gène récepteur ccr5 pour protéger contre l'infection par le vih
EP3565608A4 (fr) * 2017-01-05 2020-12-16 Rutgers, The State University of New Jersey Plate-forme d'édition génique ciblée indépendante de la cassure bicaténaire de l'adn et ses utilisations
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) * 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CN110446782B (zh) 2017-03-22 2024-03-01 国立大学法人神户大学 一种改变细胞所具有的dna的靶向部位的方法以及用于该方法的复合体
KR20190130613A (ko) 2017-03-23 2019-11-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
CN107384920B (zh) * 2017-05-10 2020-07-14 中山大学 一套基于化脓性链球菌的碱基编辑系统及其在基因编辑中的应用
WO2018209320A1 (fr) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
JP2020521446A (ja) * 2017-05-25 2020-07-27 ザ ジェネラル ホスピタル コーポレイション 二部塩基エディター（ｂｂｅ）構造およびｉｉ型−ｃ−ｃａｓ９ジンクフィンガー編集
WO2019023680A1 (fr) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace)
CN111263812A (zh) * 2017-07-31 2020-06-09 西格马-奥尔德里奇有限责任公司 用于crispr/cas激活系统的合成的指导rna
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019099943A1 (fr) * 2017-11-16 2019-05-23 Astrazeneca Ab Compositions et méthodes pour améliorer l'efficacité de stratégies knock-in basées sur cas9
KR102647714B1 (ko) 2018-03-19 2024-03-18 리제너론 파마슈티칼스 인코포레이티드 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
CN108949830B (zh) * 2018-08-03 2021-11-26 福州大学 一种在鱼类中实现基因组编辑、精确定点基因敲入的方法
CN110878321B (zh) * 2018-09-06 2023-08-22 上海科技大学 一种用于肺炎克雷伯菌基因编辑的表达载体
CN109385425A (zh) * 2018-11-13 2019-02-26 中山大学 一种高特异性ABE碱基编辑系统及其在β血红蛋白病中的应用
US11946040B2 (en) 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing
CN116497067A (zh) 2019-02-13 2023-07-28 比姆医疗股份有限公司 治疗血红素病变的组合物和方法
EP3942040A1 (fr) 2019-03-19 2022-01-26 The Broad Institute, Inc. Procédés et compositions pour l'édition de séquences nucléotidiques
US20220235348A1 (en) * 2019-05-15 2022-07-28 Board Of Regents, The University Of Texas System Crispr methods for treating cancers
JP2022533673A (ja) * 2019-05-21 2022-07-25 ビーム セラピューティクス インク． プログラム可能塩基エディターシステムを用いた一塩基多型編集法
EP4008784A1 (fr) * 2019-08-01 2022-06-08 Astellas Pharma Inc. Arn guide pour édition ciblée avec séquence de base fonctionnelle ajoutée à celui-ci
EP3783104A1 (fr) * 2019-08-20 2021-02-24 Kemijski Institut Connexion à médiation de superhélice de crispr-cas et d'exonucléases pour améliorer l'édition de génomes
CN112481309B (zh) * 2019-09-12 2023-10-10 石家庄埃佤基因科技有限公司 Ago蛋白的用途及组合物和基因编辑方法
WO2021081264A1 (fr) 2019-10-24 2021-04-29 Pairwise Plants Services, Inc. Nucléases crispr-cas optimisées et éditeurs de base et leurs méthodes d'utilisation
CA3159944A1 (fr) 2019-12-02 2021-06-10 David HUSS Edition therapeutique
CN115667283A (zh) * 2020-03-03 2023-01-31 小利兰斯坦福大学董事会 Rna指导的千碱基规模基因组重组工程
BR112022017704A2 (pt) * 2020-03-04 2022-11-01 Suzhou Qi Biodesign Biotechnology Company Ltd Método e sistema de edição de genoma multiplex
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
US20230235315A1 (en) 2020-07-10 2023-07-27 Horizon Discovery Limited Method for producing genetically modified cells
CA3196996A1 (fr) * 2020-11-19 2022-05-27 Baisong Lu Vecteurs, systemes et procedes d'edition de genes eucaryotes
US20240067954A1 (en) 2021-01-05 2024-02-29 Horizon Discovery Limited Method for producing genetically modified cells
US20240067983A1 (en) * 2021-01-05 2024-02-29 Horizon Discovery Limited Guide RNA Designs and Complexes for Tracr-less Type V Cas Systems
US20240060088A1 (en) * 2021-01-05 2024-02-22 Horizon Discovery Limited Guide RNA Designs and Complexes for Type V Cas Systems
GB202107671D0 (en) 2021-05-28 2021-07-14 Asociacion Centro De Investig Cooperativa En Nanociencias Cic Nanogune Synthetic cas proteins
EP4347808A2 (fr) 2021-05-25 2024-04-10 ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN NANOCIENCIAS "CIC nanoGUNE" Protéines cas synthétiques
WO2024096790A1 (fr) * 2022-10-31 2024-05-10 Soledits Ab Système crispr modulaire
CN116726198B (zh) * 2023-03-13 2024-02-13 陕西师范大学 一种抗肿瘤药物及其在脑胶质瘤治疗中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089406A1 (fr) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Variantes genetiques de cas pour l'edition genique
WO2015133554A1 (fr) 2014-03-05 2015-09-11 国立大学法人神戸大学 Procédé de modification de séquence génomique permettant la conversion de façon spécifique de bases d'acide nucléique de séquences d'adn ciblées et complexe moléculaire destiné à être utilisée dans ce dernier

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63258A (en) 1867-03-26 David king
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US5061641A (en) 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
WO1994012520A1 (fr) 1992-11-20 1994-06-09 Enzon, Inc. Segment de liaison pour polypeptides fusionnes lies
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
WO2008002661A2 (fr) 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Constructions génétiques de type protéine de fusion
US8202983B2 (en) 2007-05-10 2012-06-19 Agilent Technologies, Inc. Thiocarbon-protecting groups for RNA synthesis
US20110104787A1 (en) 2009-11-05 2011-05-05 President And Fellows Of Harvard College Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
SI2697257T1 (sl) 2011-04-13 2017-02-28 Bristol-Myers Squibb Company FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
PT2800811T (pt) 2012-05-25 2017-08-17 Univ California Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição
HUE035607T2 (en) 2012-06-25 2018-05-28 Brigham & Womens Hospital Inc Targeted therapeutic agents
EP3825401A1 (fr) 2012-12-12 2021-05-26 The Broad Institute, Inc. Systèmes de composants crispr-cas, procédés et compositions pour la manipulation de séquence
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3553174A1 (fr) 2012-12-17 2019-10-16 President and Fellows of Harvard College Ingénierie de génome humain guidée par arn
CN105103045A (zh) 2012-12-18 2015-11-25 兰斯维克托公司 具有高级电场控制能力的液晶光学设备
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CN110540991B (zh) 2013-03-15 2023-10-24 通用医疗公司 使用截短的引导RNA(tru-gRNA)提高RNA引导的基因组编辑的特异性
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
CN105492611A (zh) 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
WO2015089486A2 (fr) 2013-12-12 2015-06-18 The Broad Institute Inc. Systèmes, procédés et compositions pour manipulation de séquences avec systèmes crispr-cas fonctionnels optimisés
EP3985124A1 (fr) * 2013-12-26 2022-04-20 The General Hospital Corporation Arn guides multiplex
PL3105328T3 (pl) * 2014-02-11 2020-10-19 The Regents Of The University Of Colorado, A Body Corporate Umożliwiana przez CRISPR multipleksowa modyfikacja genomu
US20170233762A1 (en) * 2014-09-29 2017-08-17 The Regents Of The University Of California Scaffold rnas
KR102531016B1 (ko) 2014-11-21 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
JP7044373B2 (ja) 2015-07-15 2022-03-30 ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
IL294014B1 (en) 2015-10-23 2024-03-01 Harvard College Nucleobase editors and their uses
EP3565608A4 (fr) 2017-01-05 2020-12-16 Rutgers, The State University of New Jersey Plate-forme d'édition génique ciblée indépendante de la cassure bicaténaire de l'adn et ses utilisations
AU2022324118A1 (en) 2021-08-06 2024-02-22 Horizon Discovery Limited Method for producing genetically modified cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089406A1 (fr) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Variantes genetiques de cas pour l'edition genique
WO2015133554A1 (fr) 2014-03-05 2015-09-11 国立大学法人神戸大学 Procédé de modification de séquence génomique permettant la conversion de façon spécifique de bases d'acide nucléique de séquences d'adn ciblées et complexe moléculaire destiné à être utilisée dans ce dernier

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZALATAN, J.G., et al.，"Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds."，CELL，2015年01月15日，Vol.160, No.1-2，pp.339-350，doi: 10.1016/j.cell.2014.11.052

Also Published As

Publication number Publication date
EP3322804A1 (fr) 2018-05-23
CN108291218B (zh) 2022-08-19
CA2992580A1 (fr) 2017-01-19
WO2017011721A1 (fr) 2017-01-19
US20180327784A1 (en) 2018-11-15
CA3168241A1 (fr) 2017-01-19
EP3957731A1 (fr) 2022-02-23
JP7364268B2 (ja) 2023-10-18
EP3322804B1 (fr) 2021-09-01
CN108291218A (zh) 2018-07-17
JP2018520686A (ja) 2018-08-02
US20220267806A1 (en) 2022-08-25
US11479793B2 (en) 2022-10-25
CA2992580C (fr) 2022-09-20
EP3322804A4 (fr) 2019-01-30
JP2022095633A (ja) 2022-06-28
HK1258288A1 (zh) 2019-11-08
DK3322804T3 (da) 2021-10-04
ES2892625T3 (es) 2022-02-04

Similar Documents

Publication Publication Date Title
JP7044373B2 (ja) ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
JP7219972B2 (ja) Ｄｎａ二本鎖切断に非依存的な標的化遺伝子編集プラットフォームおよびその用途
JP6878468B2 (ja) 標的ゲノム修飾を増強するためのプログラム可能なｄｎａ結合タンパク質の使用
DK3138912T3 (en) CRISPR-BASED RE-MODIFICATION AND REGULATION
ES2784754T3 (es) Métodos y composiciones para modificar un locus objetivo
DK3161128T3 (en) METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
JP7109547B2 (ja) 真核ゲノム修飾のための操作されたＣａｓ９システム
ES2267567T3 (es) Recombinacion de adn especifica de secuencia en celulas eucariotas.
KR20150105475A (ko) 유각의 가축
KR20210105914A (ko) 뉴클레아제-매개 반복부 팽창
CN110891419A (zh) 评价crispr/cas-诱导的与外源供体核酸的体内重组
JP2022520104A (ja) Ｃｒｉｓｐｒ／ｃａｓ融合タンパク質およびシステム
KR20220128644A (ko) 게놈 변형을 위한 높은 충실도 SpCas9 뉴클라제
US20220162648A1 (en) Compositions and methods for improved gene editing
WO2024097747A2 (fr) Fusions de recombinase d'adn
KR20190038449A (ko) Klotho 유전자 넉아웃 질환모델 동물 및 이의 용도

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200923

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220310

R150 Certificate of patent or registration of utility model

Ref document number: 7044373

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150